loader2
Partner With Us NRI

Piramal Pharma Ltd share Price Today

Company details

146.55
149.75
71.78
166.70
6M Return 22.60%
1Y Return 99.38%
Mkt Cap.(Cr) 19,447.34
Volume 2,567,855
Div Yield 0.00%
OI
-
OI Chg %
-
Volume 2,567,855

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Pharmaceuticals company Piramal Pharma announced Q4FY24 & FY24 results:

  • Revenue from Operations grew by 18% YoY and 15% YoY in Q4FY24 and FY24 respectively, driven by healthy growth in our CDMO and ICH businesses
  • EBITDA grew by 48% YoY and 61% YoY in Q4FY24 and FY24 respectively, primarily driven by revenue growth, operating leverage, cost optimization, and operational excellence initiatives
  • Net Profit After Tax (before exceptional Items) more than doubled in Q4FY24 at Rs 132 crore compared to Rs 50 crore in Q4FY23
  • Net Debt / EBITDA improved from 5.6x at the start of the financial year to 2.9x at the end of FY24 

Nandini Piramal, Chairperson, Piramal Pharma Limited said, “FY24 has been a strong year for the Company with all round improvement, mainly driven by our CDMO business that delivered a robust 19% YoY revenue growth. We saw significant increase in order inflows, especially for on-patent commercial manufacturing, amidst a difficult biotech funding environment. Contributions from our innovation related work and differentiated offerings also increased in FY24. Capacity expansion at our Grangemouth facility for Antibody Drug Conjugate segment was commercialized and is seeing good customer interest.

In the Inhalation anesthesia business, we continue to maintain our leading position in Sevoflurane in the US market and are expanding our capacities to tap the growing demand in the ROW markets. Our India Consumer Healthcare business is also continuing to perform well with focus on better EBITDA margin.

During the year, we also showed a significant improvement in our profitability with EBITDA margin of 17% (Vs. 12% in FY23). All our three businesses delivered higher EBITDA margins through operating leverage, cost optimization, and operational excellence initiatives. Our Net Debt / EBITDA ratio also improved significantly, as we ended the financial year below 3x compared to 5.6x at the start of the year.”

Result PDF

View Other Company Results

Piramal Pharma Ltd shares SWOT Analysis

Strengths (11)

  • Rising Net Cash Flow and Cash from Operating activity
  • Company with high TTM EPS Growth
  • Strong Annual EPS Growth

Weakness (0)

Data not found

Opportunity (2)

  • Street Favorite: High Analyst Rating with at least 20% upside
  • Highest Recovery from 52 Week Low

Threats (1)

  • High PE (PE > 40)

Resistance and support

R1 149.0
R2 151.0
R3 152.2
Pivot

147.77

S1 145.8
S2 144.6
S3 142.6
EMA SMA
147.1
141.6
135.7
126.8
147.9
137.4
137.8
123.1
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
EAST BRIDGE CAPITAL MASTER FUND I LIMITED Bulk Purchase 2023-10-31 102.8 33643099 BSE
EAST BRIDGE CAPITAL MASTER FUND LIMITED Bulk Sell 2023-10-31 102.8 33643099 BSE
EAST BRIDGE CAPITAL MASTER FUND I LIMITED Block Purchase 2023-10-31 102.8 33643099 BSE
Name Category Shares
The Sri Krishna Trust through its Trustee Mr. Ajay G Piramal and Dr. (Mrs.) Swati A Piramal PROMOTER 26.67%
V3 Designs LLP PROMOTER 3.25%
PRL Realtors LLP PROMOTER 3.01%
Piramal Welfare Trust (Formerly known as The Piramal Enterprise Executives Trust) PROMOTER 0.8%
AASAN Corporate Solutions Pvt. Ltd PROMOTER 0.68%

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Piramal Pharma Ltd Stocks COMPARISON

Financials( in Cr) Piramal Pharma Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Zydus Lifesciences Ltd Divis Laboratories Ltd
Price 147.00 1,539.30 1,482.30 1,080.65 4,058.55
% Change 0 -0.11 2.77 -0.71 1.05
Mcap Cr 19,447.34 369,329.64 119,676.01 108,738.68 107,741.92
Revenue TTM Cr 7,081.55 43,885.68 15,790.60 17,237.40 7,767.51
Net Profit TTM Cr -186.46 8,560.84 2,513.47 1,997.30 1,823.38
PE TTM 0.00 39.39 28.09 28.10 77.94
1 Year Return 99.38 64.20 60.26 113.46 24.30
ROCE 1.90 16.79 14.76 16.25 19.30
ROE -2.77 16.46 10.66 14.05 14.89
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 6,773.50 Cr FV: 10.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 41,960.24 -29,509.50
LAST 3M 102,987.80 -35,737.56
LAST 6M 169,824.52 46,518.61
LAST 12M 263,691.56 126,663.80
Piramal Pharma Limited - Analysts/Institutional Investor Meet/Con. Call Updates

May 18, 2024 l NSE Announcement

Piramal Pharma Limited - Analysts/Institutional Investor Meet/Con. Call Updates

May 17, 2024 l NSE Announcement

Piramal Pharma Limited - Disclosure under SEBI Takeover Regulations

May 16, 2024 l NSE Announcement

Date Action Type Ratio
No data found

Piramal Pharma Ltd Information

Stock PE (TTM)
0
Promoter Holding
35.02%
Book Value
59.801
ROCE
1.9%
ROE
-2.77%
Description
  • Piramal Pharma Limited was incorporated on March 4, 2020 as a Public Limited Company and registered with the RoC. The Company offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries. It includes an integrated CDMO business, CHG business and ICH business, selling over-the-counter products in India. In addition, it has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. Piramal Pharma Solution provides integrated drug discovery, development, and manufacturing services for both drug substances, i.e. active pharmaceutical ingredients (APIs) and drug products, i.e. formulations across the life cycle of a molecule, from discovery and clinical development to commercial launch. In addition, the Company has a joint venture (Allergan India Private Limited) with Allergan (now AbbVie), one of the market leaders in ophthalmology in the Indian formulations market. PPL holds 49% of the paid-up equity share capital in the joint venture. Further, PPL has a minority investment of 33.33% in Yapan Bio that operates in the biologics/ bio-therapeutics and vaccine segments. The Company is among the leading players in India in the self-care space, with established brands like Saridon, Supradyn, Lacto Calamine, Little`s, Tetmosol, i-Pill and Polycrol. Apart from this, the Company offers differentiated capabilities in niches areas such as highly potent APIs, antibody drug conjugates, potent sterile injectables, hormonal oral solid dosage forms and biologics and vaccines. It has a global footprint with manufacturing capabilities across 15 facilities spanning across India, US, the UK and Canada. It also has global distribution network in over 100 countries. The Company`s global distribution network gives it access to offer services and products to customers including large global pharma companies, biotech companies, hospitals and institutions. In June 2020, the Company acquired pharmaceutical business from Piramal Enterprises Limited (PEL). In October 2020, the Company received growth equity investment from the Carlyle Group. In It acquired 100% stake in Convergence Chemicals Private Limited (CCPL). It announced expansion for antibody drug conjugates at its Grangemouth (UK) facility and expansion of drug substance capabilities at its Riverview facility (USA). In 2021, it acquired Hemmo Pharmaceuticals Private Limited (HPPL), into the development and manufacturing of peptide APIs. On 7th October 2021, the Composite Scheme of Arrangement, which was entered into between the Company, Piramal Pharma Limited (PPL), Convergence Chemicals Private Limited (CCPL), Hemmo Pharmaceuticals Private Limited (HPPL), PHL Fininvest Private Limited (PFPL) and their respective shareholders and creditors for demerger of Pharma Business from Piramal Enterprises Limited (PEL) to PPL, amalgamation of CCPL and HPPL (both being wholly owned subsidiaries of PPL) into PPL; and the amalgamation of PFPL (a wholly owned subsidiary of PEL) into PEL was effective from August 18, 2022. In consideration for the demerger, the equity shareholders of PEL as on the demerger record date received 4 equity shares of face and paid-up value of Rs 10 each of the Company for every 1 equity share of face and paid-up value of Rs 2 each held in PEL. i.e. 4:1. Accordingly, the Company was listed on the Stock Exchanges, BSE Limited (BSE) and National Stock Exchange of India Limited `NSE) on October 19, 2022. In 2022, the Company acquired minority stake in Yapan Bio Private Limited, an India-Based CDMO providing expertise in biologics and vaccines. It launched 26 New products and 37 new SKUs during FY 2023.

Registered Address

Ground Floor Piramal Ananta, Agastya Corp.Park LBS MargKurl, Mumbai, Maharashtra, 400070

Tel : 91-22-3802-3000/4000
Email : corporate.secretarial:piramal.com
Website : http://www.piramalpharma.com
Registrar

Link Intime India Pvt Ltd

AGM Date (Month) : Jul
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 543635
NSE Code : PPLPHARMA
Book Closure Date (Month) :
BSE Group : A
ISIN : INE0DK501011

FAQ’s on Piramal Pharma Ltd Shares

You can buy Piramal Pharma Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Piramal Pharma Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of May 22, 2024 03:59 PM the closing price of Piramal Pharma Ltd was Rs.147.00.

Market capitalization or market cap is determined by multiplying the current market price of a company�s shares with the total number of shares outstanding. As of May 22, 2024 03:59 PM, the market cap of Piramal Pharma Ltd stood at Rs. 19,447.34.

The latest PE ratio of Piramal Pharma Ltd as of May 22, 2024 03:59 PM is 0.00

The latest PB ratio of Piramal Pharma Ltd as of May 22, 2024 03:59 PM is 0.41

The 52-week high of Piramal Pharma Ltd share price is Rs. 166.70 while the 52-week low is Rs. 71.78

Download App

Download Our App

Play Store App Store
market app